When the specter of healthcare reform last raised its head, in 1993, the biopharmaceutical industry believed it saw the face of the enemy in Hillary Rodham Clinton. Today the former first lady is facing off the likes of Vladimir Putin as Secretary of State, and the industry is once again quaking at the prospect of Read more »
Assemble a panel of the biopharmaceutical industry’s elder statesmen to compare the last 15 years with the prognosis for the future and you risk hearing a rendition of the Kinks’ classic song, “Where Have all the Good Times Gone.”
Happily the four self-described grey beards on BioPharm America’s second plenary session of the day in San Read more »
Lately the biopharmaceutical industry’s classic research and development strategy resembles the patient in Monty Python’s plague sketch. While it keeps insisting that it’s not dead yet, it’s “not at all well.”
There are any number of ways to plot the industry’s productivity, but all of the graphs show curves going the wrong way. R&D Read more »
Welcome to the San Francisco Bay Area, a region whose name is synonymous with innovation. Over the past 30 years a potent cocktail of talented entrepreneurs, smart venture capitalists, vibrant research institutions and dose of “can do” Californian optimism has made San Francisco into the biotech capital of the world.
Iconic industry names Read more »
CEO George Scangos and dealmaker Fran Heller
George Scangos, President and CEO of Exelixis, re-energized a troubled biotech industry, according to the Wall Street Journal, when he announced earlier this year he had licensed two cancer drugs to French pharmaceutical giant Sanofi-aventis with an upfront payment of USD 140 million.
The news came on the heels of Read more »
Jack M. Anthony, CEO of Osprey Pharmaceuticals USA, has enjoyed a rich and varied career across a range of biotechnology start-ups thanks to a love of biology and a passion for dealmaking. He has concluded agreements valued over USD 3 billion to date.
Anthony will moderate a panel discussion at BioPharm America 2009 in San Francisco Read more »
Big pharma is taking a well deserved rest from the megamerger mania that gripped the industry during the first half of 2009. Now that Roche has got Genentech, and Pfizer is getting together with Wyeth, and Merck is taking Schering-Plough, there are only about a dozen bona fide big pharmas left on the global playing Read more »
Newsletter